183 related articles for article (PubMed ID: 33207133)
1. Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings.
Wibmer AG; Chaim J; Lakhman Y; Lefkowitz RA; Nincevic J; Nikolovski I; Sala E; Gonen M; Carlsson SV; Fine SW; Zelefsky MJ; Scardino P; Hricak H; Vargas HA
J Urol; 2021 Apr; 205(4):1055-1062. PubMed ID: 33207133
[TBL] [Abstract][Full Text] [Related]
2. Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.
Wibmer AG; Nikolovski I; Chaim J; Lakhman Y; Lefkowitz RA; Sala E; Carlsson SV; Fine SW; Kattan MW; Hricak H; Vargas HA
Radiology; 2022 Mar; 302(3):595-602. PubMed ID: 34931855
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
4. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
Mazzone E; Gandaglia G; Ploussard G; Marra G; Valerio M; Campi R; Mari A; Minervini A; Serni S; Moschini M; Marquis A; Beauval JB; van den Bergh R; Rahota RG; Soeterik T; Roumiguiè M; Afferi L; Zhuang J; Guo H; Mattei A; Gontero P; Cucchiara V; Stabile A; Fossati N; Montorsi F; Briganti A
Eur Urol; 2022 Feb; 81(2):193-203. PubMed ID: 34399996
[TBL] [Abstract][Full Text] [Related]
5. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
6. Lesion size on prostate magnetic resonance imaging predicts adverse radical prostatectomy pathology.
Tonttila PP; Kuisma M; Pääkkö E; Hirvikoski P; Vaarala MH
Scand J Urol; 2018 Apr; 52(2):111-115. PubMed ID: 29291666
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
[TBL] [Abstract][Full Text] [Related]
9. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
11. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
12. The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy.
Morlacco A; Sharma V; Viers BR; Rangel LJ; Carlson RE; Froemming AT; Karnes RJ
Eur Urol; 2017 May; 71(5):701-704. PubMed ID: 27576750
[TBL] [Abstract][Full Text] [Related]
13. Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis.
Kongnyuy M; Sidana A; George AK; Muthigi A; Iyer A; Ho R; Chelluri R; Mertan F; Frye TP; Su D; Merino MJ; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Urol Oncol; 2017 Jan; 35(1):30.e1-30.e8. PubMed ID: 27567248
[TBL] [Abstract][Full Text] [Related]
14. MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.
Wibmer AG; Lefkowitz RA; Lakhman Y; Chaim J; Nikolovski I; Sala E; Fine SW; Donahue TF; Kattan MW; Hricak H; Vargas HA
Clin Genitourin Cancer; 2022 Aug; 20(4):319-325. PubMed ID: 35618599
[TBL] [Abstract][Full Text] [Related]
15. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison between multiparametric MRI, the partin tables, memorial sloan kettering cancer center nomogram, and CAPRA score in predicting extraprostatic cancer in patients undergoing radical prostatectomy.
Zanelli E; Giannarini G; Cereser L; Zuiani C; Como G; Pizzolitto S; Crestani A; Valotto C; Ficarra V; Girometti R
J Magn Reson Imaging; 2019 Nov; 50(5):1604-1613. PubMed ID: 30957321
[TBL] [Abstract][Full Text] [Related]
17. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
18. Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with
Sobol I; Zaid HB; Haloi R; Mynderse LA; Froemming AT; Lowe VJ; Davis BJ; Kwon ED; Karnes RJ
J Urol; 2017 Jan; 197(1):129-134. PubMed ID: 27449262
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
Cooperberg MR; Broering JM; Carroll PR
J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
[TBL] [Abstract][Full Text] [Related]
20. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer.
Rayn KN; Bloom JB; Gold SA; Hale GR; Baiocco JA; Mehralivand S; Czarniecki M; Sabarwal VK; Valera V; Wood BJ; Merino MJ; Choyke P; Turkbey B; Pinto PA
J Urol; 2018 Nov; 200(5):1041-1047. PubMed ID: 29852182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
